General Practice Doctors in Akron, OH Accepting Medicare

6 General Practice doctors found. Showing 1 - 6

Mandakini Y Tamaskar, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 400 Wabash Ave, Akron, OH 44307 Phone: 330-344-6000

Garry L. Thrasher, D.O. General Practice Medicare: Not Enrolled in Medicare Practice Location: 15 Frederick Ave, Akron, OH 44310 Phone: 330-714-3214

Christmas V Salapare, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 400 Wabash Ave, Akron, OH 44307 Phone: 330-344-6000

Chris Marquart, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 1450 Firestone Pkwy Ste F, Akron, OH 44301 Phone: 330-724-3345    Fax: 330-724-5299

Prahladkumar J Agarwal, MD General Practice Medicare: Medicare Enrolled Practice Location: 190 N Union St Ste 203, Akron, OH 44304 Phone: 330-923-3502    Fax: 330-923-9761

Asegedech Shimellis, MD General Practice Medicare: Medicare Enrolled Practice Location: 1 Akron General Ave, Akron, OH 44307 Phone: 330-344-6000

News Archive

Common risk factors for behavioral problems in US, Great Britain children

Children in the United States and Great Britain share a number of common risk factors that increase the likelihood that they will have behavioral problems-and Britain's broader social welfare programs don't appear to mitigate those risks, according to a new study in the June issue of the Journal of Health and Social Behavior (JHSB).

Ebola virus vaccines for humans

One of the world's deadliest diseases, caused by the Ebola virus, may finally be preventable thanks to US and Canadian researchers, who have successfully tested several Ebola vaccines in primates and are now looking to adapt them for human use.

Scientists study about rare type of skin cancer, acral melanomas

Acral melanomas, the rare type of skin cancer that caused musician Bob Marley's death, are genetically distinct from other types of skin cancer.

FDA accepts Arena Pharmaceuticals' lorcaserin NDA

Arena Pharmaceuticals, Inc. announced today that its New Drug Application (NDA) for lorcaserin, Arena's internally discovered and developed drug candidate for weight management, including weight loss and maintenance of weight loss, has been accepted for filing by the US Food and Drug Administration (FDA). Arena submitted the lorcaserin NDA on December 22, 2009, and expects to learn the Prescription Drug User Fee Act (PDUFA) date in the next few weeks. The PDUFA date is the target date for the FDA to complete its review of an NDA.

Biomarkers help resolve differential diagnosis between MPM and non-cancerous pleural tissue

Scientists have identified four biomarkers that may help resolve the difficult differential diagnosis between malignant pleural mesothelioma (MPM) and non-cancerous pleural tissue with reactive mesothelial proliferations (RMPs).

Read more Medical News

› Verified 8 days ago